IMS Health and SDI issued the following statement today regarding
the First Circuit Court of Appeals' decision to overturn a New
Hampshire U.S. District Court ruling that struck down the State's law
banning the commercial use of prescriber-identifiable data.
"We are disappointed with the First Circuit Court of Appeals decision.
Two federal courts previously have examined the issue and validated
the view that the First Amendment protects the dissemination of
prescriber-identifiable data, which we believe is vital to efforts to
improve the quality, efficiency and safety of our healthcare system.
We are currently reviewing the decision and evaluating potential next
steps."
About IMS
Operating in more than 100 countries, IMS Health is the world's leading
provider of market intelligence to the pharmaceutical and healthcare
industries. With $2.2 billion in 2007 revenue and more than 50 years of
industry experience, IMS offers leading-edge market intelligence products
and services that are integral to clients' day-to-day operations, including
portfolio optimization capabilities; launch and brand management solutions;
sales force effectiveness innovations; managed care and consumer health
offerings; and consulting and services solutions that improve ROI and the
delivery of quality healthcare worldwide. Additional information is available at
http://www.imshealth.com.
About SDI
On July 29th, 2008 Verispan, LLC was acquired by SDI. Since 1982, SDI has
been delivering innovative healthcare data products and analytic services to
the pharmaceutical, biotech, healthcare, medical device, financial services,
and consumer packaged goods industries. SDI is the leading provider of deidentified
patient-level data analytics and offers a broad array of solutions
and insights across the continuum of care. These include custom and
syndicated patient-level data studies; localized disease and treatment
surveillance and projection; market research audits; healthcare profiles;
comprehensive managed care offerings; clinical trial optimization; direct-topatient
pharmacy programs; marketing effectiveness; sales targeting and
compensation products; data integration, warehousing, and mining; list
services; and direct marketing services. Its current roster includes the top 50
pharmaceutical/biotech companies. For more information, visit
www.sdihealth.com or call 610.834.0800.